Half of advanced melanoma patients live for 10 years with double drug treatment
Briefly

from www.theguardian.com3 weeks ago
More than half of patients diagnosed with advanced melanoma now survive for at least 10 years thanks to combined immunotherapy treatments, a significant increase from previous survival rates.
www.theguardian.comhttps://www.theguardian.com/society/2024/sep/15/double-drug-treatment-raises-survival-rate-for-half-of-advanced-melanoma-to-10-years
James Larkin emphasized that some patients treated with the immunotherapy have experienced what can be defined as a cure, as they return to their normal lives after treatment.
www.theguardian.comhttps://www.theguardian.com/society/2024/sep/15/double-drug-treatment-raises-survival-rate-for-half-of-advanced-melanoma-to-10-years
The trial involved 945 patients and demonstrated that the combination of ipilimumab and nivolumab significantly enhances the melanoma-specific survival rate, showing that patients can live long enough to die from unrelated causes.
www.theguardian.comhttps://www.theguardian.com/society/2024/sep/15/double-drug-treatment-raises-survival-rate-for-half-of-advanced-melanoma-to-10-years
This year's expected diagnoses of over 20,000 melanoma cases in the UK highlights a pressing public health message, as the vast majority of melanoma cases are preventable through sun exposure awareness.
www.theguardian.comhttps://www.theguardian.com/society/2024/sep/15/double-drug-treatment-raises-survival-rate-for-half-of-advanced-melanoma-to-10-years
Read at www.theguardian.com
#immunotherapy #melanoma #cancer-treatment #survival-rates #public-health
[
]
[
|
]